Cohance Lifesciences Q2 profit plunges 79.5% to ₹15.2 crore
In short
Cohance Life Sciences reported a sharp drop in Q2 FY27. Net profit fell 79.5% to ₹15.2 crore, and revenue declined 14.2% to ₹477 crore.
The company expects a much stronger second half, supported by Small Molecule deliveries, reload orders, nucleic-acid growth and better portfolio performance.
What the reporting says
Cohance Life Sciences reported a 79.5% year-on-year drop in Q2 FY27 net profit to ₹15.2 crore, while revenue fell 14.2% to ₹477 crore. The company said the weaker quarter reflected lower revenue and an unfavourable product mix. It expects a materially stronger second half, helped by Small Molecule deliveries, reload orders, nucleic-acid growth and better portfolio performance.
Why it matters
Cohance Life Sciences reported Q2 FY27 net profit of ₹15.2 crore, down 79.5% year on year, while revenue fell 14.2% to ₹477 crore. The company linked the weak quarter to lower revenue and an unfavourable product mix. It expects a stronger second half, citing Small Molecule deliveries, reload orders, nucleic-acid growth and improved portfolio performance.